FDA 483 - NATCO Pharma Limited - June 05, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of NATCO Pharma Limited, a sterile and non-sterile finished drug manufacturer in Rangareddy, India, revealed significant deficiencies across multiple systems. The firm failed to adhere to quality control unit responsibilities, maintain adequate laboratory controls, follow written procedures for annual product reviews and investigations, and ensure proper equipment calibration. These issues indicate a systemic lack of compliance with cGMP regulations.
ID · 0bf5ef08-8bd5-4fcd-a591-64b19920b76d